Anygen (196300) Stock Overview

Anygen Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide APIs and drug development in South Korea and internationally. It develops GMP, generic, custom, and catalog peptides, as well as offers other services. The company is also developing AGM-130 for breast cancer; AGM-212 for type 2 diabetes; AGM-251 for neuropathic pain; and AGM-290 for MRSA infection treatment. Anygen Co., Ltd. was founded in 2000 and is headquartered in Gwangju-si, South Korea.